Regional Health Properties Reports Third Quarter 2026 Results
Revenue surged but profitability reversed, with net loss replacing last year’s net income.
What the company is saying
Regional Health Properties, Inc. highlights a 65% year-over-year revenue increase to $25.0 million for Q3 2026, attributing growth to the addition of Pharmacy Services via the SunLink merger and higher patient care revenues. The company frames its narrative around operational improvements, increased portfolio occupancy to 76.0%, and a transformation toward an integrated healthcare model. Management, led by President and CEO Brent Morrison, emphasizes capturing more value from facility operations and ongoing efforts to improve profitability and free cash flow. The company also points to the repurchase of 15,829 Series B Preferred Shares at a discount as a positive capital action. Forward-looking statements focus on evaluating refinancing and liquidity alternatives, particularly for the Southland facility and other mortgage loans. The tone is measured, acknowledging progress but stressing that further work is needed to achieve sustainable profitability.
What the data suggests
Revenue rose sharply to $25.0 million from $15.1 million in Q3 2025, driven by $9.5 million in Pharmacy Services revenue and a $4.9 million increase in patient care revenues to $14.7 million. Despite these gains, the company swung from a $3.7 million net profit last year to a $0.9 million net loss this quarter. Adjusted EBITDA improved to $1.2 million from $0.2 million, indicating better operational performance but not enough to offset higher expenses, which totaled $24.7 million excluding impairment. Portfolio occupancy improved to 76.0% from 67.3%. Cash on hand was limited, with $1.7 million unrestricted and $3.2 million restricted, against $42.2 million in net debt. The company’s preferred share repurchase reduced Series B outstanding shares but did not materially alter the overall leverage profile. The data reveals that while operational metrics are trending positively, financial pressures persist and profitability remains elusive.
Analysis
The announcement is a factual quarterly financial disclosure, providing detailed realised figures for revenue, net loss, adjusted EBITDA, occupancy, cash, and debt. The majority of claims are backward-looking and supported by numerical data, with only a small portion referencing forward-looking activities such as evaluating refinancing and liquidity alternatives. There is no exaggerated or promotional language; the tone is measured and consistent with standard financial reporting. While revenue and adjusted EBITDA improved year-over-year, the company swung from net income to a net loss, which is transparently disclosed. The only forward-looking statements are routine (evaluating refinancing options) and do not overstate future benefits or imminent turnarounds. No large capital outlay is announced, and all key financial impacts are immediate and quantified.
Risk flags
- ●Profitability risk is high: the company moved from a $3.7 million net profit in Q3 2025 to a $0.9 million net loss in Q3 2026, despite strong revenue growth. This suggests that expense growth or margin pressures are outpacing top-line gains.
- ●Liquidity risk remains acute: unrestricted cash stood at just $1.7 million against $42.2 million in net debt, limiting flexibility to absorb shocks or fund further improvements without refinancing.
- ●Execution risk on refinancing: management is actively evaluating refinancing options for the Southland facility and other loans, but no transactions have closed. Failure to secure favorable terms could constrain future operations or growth.
- ●Integration risk from the SunLink merger: while Pharmacy Services contributed $9.5 million in revenue, the full impact on costs, margins, and operational complexity is not yet clear, raising uncertainty about sustainable profitability.
- ●Operational improvement risk: management’s strategy relies on further gains in facility-level profitability and efficiency, but these are not yet evident in the bottom line, and there is no disclosed timeline for achieving positive free cash flow.
Bottom line
Regional Health Properties delivered strong revenue growth and improved occupancy, but rising costs and integration expenses drove a swing from profit to loss. The addition of Pharmacy Services boosted top-line results, yet the company remains under financial pressure with low cash reserves and high leverage. Management’s focus on refinancing and operational improvements is necessary but unproven, and the timeline for a return to profitability is uncertain. Investors should recognize that while operational momentum is real, the path to sustainable earnings and free cash flow is not assured. The most important takeaway is that revenue growth alone is not translating into bottom-line gains, and the company’s financial position remains fragile pending successful refinancing or further cost control.
Announcement summary
(OTCQB:RHEP) (OTCQB:RHEPA) (OTCQB:RHEPB) (OTCQB:RHEPZ) Regional Health Properties, Inc. reported revenue of $25.0 million for the third quarter ended September 30, 2026, compared with $15.1 million for the third quarter of 2025. The company reported a GAAP net loss of $0.9 million for the quarter, compared with GAAP net income of $3.7 million for the same period in 2025. Adjusted EBITDA from operations was $1.2 million, up from $0.2 million in the prior year quarter. Net loss attributable to common stockholders was $0.22 per share, compared with $1.17 per share in the third quarter of 2025. Pharmacy Services revenue was $9.5 million following the addition of the Pharmacy Services segment in connection with the SunLink merger. Patient care revenues increased to $14.7 million, driven primarily by the transition of facilities to the Healthcare Services segment and higher census across the portfolio. Portfolio occupancy was 76.0% at September 30, 2026, compared to 67.3% at September 30, 2025. The company repurchased 15,829 shares of its 12.5% Series B Cumulative Redeemable Preferred Shares during the quarter at a discount to carrying value. Regional Health Properties continued to evaluate refinancing and liquidity alternatives, including potential refinancing of the Southland facility and other mortgage loans. As of September 30, 2026, the company had $1.7 million of unrestricted cash and $3.2 million of restricted cash. Indebtedness, net of deferred financing costs and unamortized discounts, was $42.2 million as of September 30, 2026. Patient care revenues for the quarter were $14,714,000, rental revenues were $798,000, and pharmacy revenues were $9,502,000, for total revenues of $25,014,000. Total expenses, excluding impairment, were $24,686,000, and impairment loss on assets held for sale was $459,000. Loss from operations was $131,000. Interest expense, net, was $576,000. Net loss attributable to Regional Health Properties, Inc. common stockholders was $851,000. Weighted average shares of common stock outstanding were 3,925,000. As of September 30, 2026, total assets were $67,503,000 and total liabilities were $65,421,000. Preferred stock, Series B, had a redemption amount of $13,960,000 at September 30, 2026. Total fixed rate debt principal was $36,204,000 at an interest rate of 4.35% maturing May 29, 2033, and total floating rate debt principal was $6,763,000 at an interest rate of 8.67% maturing October 1, 2036. Total debt principal was $42,967,000. Adjusted EBITDA from operations for the quarter was $1,150,000.
Disagree with this article?
Ctrl + Enter to submit